Literature DB >> 15734150

Non-enzymatic hinge region fragmentation of antibodies in solution.

Armando J Cordoba1, Bao-Jen Shyong, Deirdre Breen, Reed J Harris.   

Abstract

Liquid formulations of monoclonal antibodies (MAbs) typically undergo fragmentation near the papain cleavage site in the hinge region, resulting in Fab and Fab+Fc forms. The purpose of this study was to investigate whether this fragmentation is due to proteases. Four closely-related MAbs were exchanged into a pH 5.2 acetate buffer with NaCl and stored at -20 degrees C, 5 degrees C, 30 degrees C, or 40 degrees C for 1 month. Fragmentation generated size-exclusion chromatography (SEC) peak fractions that were analyzed by electrospray mass spectrometry to identify the cleavage sites. The effects of protein inhibitors or host cell proteins on fragmentation were also studied. The extent of fragmentation was equivalent for all four antibodies, occurring in the heavy chain hinge region Ser-Cys-Asp-Lys-Thr-His-Thr sequence. The fragment due to cleavage of the Asp-Lys bond showed two forms that differ by 18 Da. A synthetic peptide with the hinge region sequence terminating with Asp did not show fragmentation or the loss of 18 Da after incubation. Protease inhibitors did not affect rates of cleavage or modify sites of fragmentation. Degradation was not affected by host cell protein content. Fragmentation appears to be a kinetic process that is not caused by low levels of host cell proteases.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15734150     DOI: 10.1016/j.jchromb.2004.12.033

Source DB:  PubMed          Journal:  J Chromatogr B Analyt Technol Biomed Life Sci        ISSN: 1570-0232            Impact factor:   3.205


  40 in total

1.  The impact of glycosylation on monoclonal antibody conformation and stability.

Authors:  Kai Zheng; Christopher Bantog; Robert Bayer
Journal:  MAbs       Date:  2011-11-01       Impact factor: 5.857

2.  Molecular mass analysis of antibodies by on-line SEC-MS.

Authors:  Lowell J Brady; John Valliere-Douglass; Theresa Martinez; Alain Balland
Journal:  J Am Soc Mass Spectrom       Date:  2008-01-04       Impact factor: 3.109

3.  Effects of subclass change on the structural stability of chimeric, humanized, and human antibodies under thermal stress.

Authors:  Takahiko Ito; Kouhei Tsumoto
Journal:  Protein Sci       Date:  2013-09-30       Impact factor: 6.725

Review 4.  Fragmentation of monoclonal antibodies.

Authors:  Josef Vlasak; Roxana Ionescu
Journal:  MAbs       Date:  2011-05-01       Impact factor: 5.857

Review 5.  Stability of protein pharmaceuticals: an update.

Authors:  Mark Cornell Manning; Danny K Chou; Brian M Murphy; Robert W Payne; Derrick S Katayama
Journal:  Pharm Res       Date:  2010-02-09       Impact factor: 4.200

Review 6.  Analytical methods for physicochemical characterization of antibody drug conjugates.

Authors:  Aditya Wakankar; Yan Chen; Yatin Gokarn; Fredric S Jacobson
Journal:  MAbs       Date:  2011-03-01       Impact factor: 5.857

Review 7.  Structure, heterogeneity and developability assessment of therapeutic antibodies.

Authors:  Yingda Xu; Dongdong Wang; Bruce Mason; Tony Rossomando; Ning Li; Dingjiang Liu; Jason K Cheung; Wei Xu; Smita Raghava; Amit Katiyar; Christine Nowak; Tao Xiang; Diane D Dong; Joanne Sun; Alain Beck; Hongcheng Liu
Journal:  MAbs       Date:  2018-12-17       Impact factor: 5.857

8.  Unbiased in-depth characterization of CEX fractions from a stressed monoclonal antibody by mass spectrometry.

Authors:  François Griaud; Blandine Denefeld; Manuel Lang; Héloïse Hensinger; Peter Haberl; Matthias Berg
Journal:  MAbs       Date:  2017-04-05       Impact factor: 5.857

9.  Host cell protein dynamics in recombinant CHO cells: impacts from harvest to purification and beyond.

Authors:  Catherine Em Hogwood; Daniel G Bracewell; C Mark Smales
Journal:  Bioengineered       Date:  2013-01-17       Impact factor: 3.269

10.  Characterization of monoclonal antibody size variants containing extra light chains.

Authors:  Connie Lu; Dandan Liu; Hongbin Liu; Paul Motchnik
Journal:  MAbs       Date:  2012-12-19       Impact factor: 5.857

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.